Postoperative Pain Clinical Pipeline | 45+ Companies, Including Oculis Pharma, Cytogel Pharma, and Camurus, Driving the Next Breakthroughs

The Postoperative Pain market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Postoperative Pain Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Postoperative Pain therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Postoperative Pain pipeline domain.

For Postoperative Pain emerging drugs, the Postoperative Pain pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies

Key Takeaways from the Postoperative Pain Pipeline Report
• DelveInsight's Postoperative Pain Pipeline analysis depicts a robust space with 45+ active players working to develop 50+ pipeline drugs for Postoperative Pain treatment.
• The leading Postoperative Pain companies include Vivozon Pharmaceutical Inc., Concentric Analgesics, LipoCure, InSitu Biologics, Bexson Biomedical, Allay Therapeutics, Jiangsu HengRui Medicine Co., Ltd., Nevakar, Inc., Oculis Pharma, Cytogel Pharma, Camurus, Taiwan Liposome Company, Teikoku Pharma USA, Salvat, Avenue Therapeutics, Cali Pharmaceuticals, Bayer, and others are evaluating their lead assets to improve the Postoperative Pain treatment landscape.
• Key Postoperative Pain pipeline therapies in various stages of development include Tramad0l, VVZ-149 Injections, OCS-01, LC-400, INSB-200, and others.
• In September 2024, the FDA approved ZYNRELEF® (bupivacaine and meloxicam) for postoperative pain management.

Request a sample and discover the recent breakthroughs happening in the Postoperative Pain pipeline landscape @ https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Postoperative Pain Overview
Postoperative or postsurgical pain is defined as pain persisting for more than 3 to 6 months following surgery. This pain differs in both quality and location from preoperative pain and is often linked to iatrogenic neuropathic pain caused by surgical injury to a major peripheral nerve. While all surgeries have the potential to result in persistent postoperative pain (PPP), certain procedures, such as inguinal hernia repair, breast and thoracic surgeries, leg amputation, and coronary artery bypass surgery, carry a higher risk due to the possibility of nerve damage. As a result, surgical techniques that minimize nerve injury should be prioritized. Postoperative pain is categorized into acute and chronic pain. Acute pain occurs immediately after surgery and typically lasts up to 7 days, while pain persisting beyond 3 months is classified as chronic. Both types of pain can originate from cutaneous, deep somatic, or visceral structures.

The pathophysiology of postoperative pain involves a combination of tissue and nerve damage induced by surgery, which triggers an injury response, including inflammation and hyperalgesia. This process alters peripheral and central nervous system (CNS) pain processing, leading to central sensitization, a key factor in the transition from acute to chronic pain. Peripheral nerve injury results in increased sodium-channel expression on sensitized primary afferent nerves, causing spontaneous activity and excessive glutamate release. This excess glutamate interacts with receptors such as NMDA, AMPA, kainate, and metabotropic glutamate receptors (mGluRs), leading to intracellular changes that contribute to sustained central sensitization. This results in heightened pain signaling, increased sensitivity to stimuli, and expanded receptive fields of central neurons. Over time, neuroplastic changes occur, transforming pain into a chronic disease state.

Effective postoperative pain management involves multiple strategies, including attentive nursing care, non-pharmacological methods such as distraction techniques, and balanced (multimodal) analgesia, which optimizes pain relief through the use of multiple analgesic agents with different mechanisms of action. This approach enhances pain control while minimizing adverse effects associated with higher doses of a single drug. Opioid analgesia remains a cornerstone of postoperative pain treatment, with commonly used intravenous opioids including morphine, hydromorphone (Dilaudid), and fentanyl. Among them, morphine is widely regarded as the standard choice due to

Find out more about Postoperative Pain medication @ https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Postoperative Pain Treatment Analysis: Drug Profile
VVZ-149: Vivozon Pharmaceutical Inc.
VVZ-149 is a new mechanism-based non-narcotic and non-NSAID analgesic demonstrating robust (comparable to morphine) pain-suppressing efficacy in a panel of in vivo models (post-operative, formalin-induced or neuropathic pain model). The compound has also shown the anti-itching effect in the serotonin-induced itching model. These in vivo efficacies are attributed to the synergistic or additive dual antagonistic activity of VVZ-149 against GlyT2 and 5HT2A, which are key receptors for the transmission of the pain signal in spinal dorsal horn area and/or peripheral sensory neurons. Currentl,y the drug is in the Phase III stage of Clinical trial evaluation for the treatment of Postoperative Pain.

LC-400: LipoCure
LC-400, is a novel Ultra-Long-Acting Local Anesthetic - ULALA, is a large multi-vesicular liposome hydrogel loaded with bupivacaine, with slow drug release and improved safety and efficacy profiles. First-in-human Phase I clinical study demonstrated excellent clinical results and the company is currently preparing for the Phase II clinical study. Currently, the drug is in the Phase I stage of its development for the treatment of postoperative pain.

Key Postoperative Pain Therapies and Companies
• IV Tramad0l: Avenue Therapeutics
• VVZ-149 Injections: Vivozon
• OCS-01: Oculis
• LC-400: LipoCure
• INSB-200: InSitu Biologics

Learn more about the novel and emerging Postoperative Pain pipeline therapies @ https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Postoperative Pain Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Postoperative Pain Pipeline Report
• Coverage: Global
• Key Postoperative Pain Companies: Vivozon Pharmaceutical Inc., Concentric Analgesics, LipoCure, InSitu Biologics, Bexson Biomedical, Allay Therapeutics, Jiangsu HengRui Medicine Co., Ltd., Nevakar, Inc., Oculis Pharma, Cytogel Pharma, Camurus, Taiwan Liposome Company, Teikoku Pharma USA, Salvat, Avenue Therapeutics, Cali Pharmaceuticals, Bayer, and others.
• Key Postoperative Pain Pipeline Therapies: Tramad0l, VVZ-149 Injections, OCS-01, LC-400, INSB-200, and others.

Dive deep into rich insights for drugs used for Postoperative Pain treatment; visit @ https://www.delveinsight.com/report-store/postoperative-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Postoperative Pain Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Postoperative Pain Pipeline Therapeutics
6. Postoperative Pain Pipeline: Late-Stage Products (Phase III)
7. Postoperative Pain Pipeline: Late-Stage Products (Phase III)
8. Postoperative Pain Pipeline: Mid-Stage Products (Phase II)
9. Postoperative Pain Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.